. . . . " "@en . . . . . . . . . "1-(2',6'-Dimethylphenoxy)-2-aminopropane"@en . . . . . . "Mexiletinum"@en . . . . . . . . "Take with food to reduce irritation."@en . . . . . . "Mexiletine"@en . . "Margarita Ortiz-Marciales, Kun Huang, Viatcheslav Stepanenko, Melvin De Jesus, Wildeliz Correa, \"Method of synthesizing enantiopure mexiletine analogues and novel b-thiophenoxy and pyridyl ethers.\" U.S. Patent US08012901, issued September 06, 2011."@en . "10-12 hours"@en . . "Well absorbed (bioavailability 90%) from the gastrointenstinal tract."@en . . . . . . . . "1-(2,6-Dimethylphenoxy)-2-propanamine"@en . . " "@en . . . . . . . . "31828-71-4"@en . . . . "Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma."@en . "For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation."@en . "Mexiletine, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals"@en . "1-Methyl-2-(2,6-xylyloxy)ethanamine"@en . . . . "Humans and other mammals"@en . "approved"@en . "* 5 to 7 L/lg"@en . . "Mexil\u00E9tine"@en . . . . . . "(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane"@en . . "50-60%"@en . . "(+-)-1-(2,6-Dimethylphenoxy)propan-2-amine"@en . . . . . . . . . "Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%."@en . "Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem]"@en . . . . . . . . . . "Mexiletina"@en . .